Key Points
- Celcuity director Richard Buller sold 3,000 shares on March 31 at an average price of $110.27 for a total of $330,810, executing the trade under a pre‑arranged Rule 10b5‑1 plan and cutting his ownership by 30.74% to 6,760 shares.
- CELC opened at $112.63 and trades near its 52‑week high ($120.32) with a $5.44B market cap; the company recently reported EPS of -$0.97 (beating estimates) and carries a consensus analyst rating of “Moderate Buy” with a $109.88 price target.
Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director Richard Buller sold 3,000 shares of the firm's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the transaction, the director directly owned 6,760 shares of the company's stock, valued at $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Celcuity Stock Down 0.3%
Shares of CELC stock opened at $112.63 on Friday. The company's fifty day simple moving average is $109.85 and its two-hundred day simple moving average is $92.26. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The stock has a market cap of $5.44 billion, a P/E ratio of -29.72 and a beta of 0.41. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20.
Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.09. Analysts predict that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on CELC shares. Wells Fargo & Company started coverage on shares of Celcuity in a report on Friday, December 12th. They issued an "overweight" rating and a $126.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Celcuity in a research note on Wednesday, January 21st. Wolfe Research reissued an "outperform" rating and set a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Stifel Nicolaus boosted their price objective on shares of Celcuity from $115.00 to $125.00 and gave the company a "buy" rating in a research report on Thursday, March 26th. Finally, Wall Street Zen upgraded shares of Celcuity from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $109.88.
Get Our Latest Stock Report on Celcuity
Institutional Investors Weigh In On Celcuity
Large investors have recently modified their holdings of the business. Ogorek Anthony Joseph NY ADV bought a new position in shares of Celcuity during the third quarter valued at approximately $27,000. EverSource Wealth Advisors LLC lifted its holdings in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after buying an additional 319 shares during the period. US Bancorp DE boosted its position in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after acquiring an additional 1,167 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in shares of Celcuity in the 4th quarter worth $42,000. Institutional investors own 63.33% of the company's stock.
About Celcuity
(
Get Free Report)
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
